<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605212</url>
  </required_header>
  <id_info>
    <org_study_id>FLO-02</org_study_id>
    <secondary_id>2016-001445-61</secondary_id>
    <nct_id>NCT03605212</nct_id>
  </id_info>
  <brief_title>Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults</brief_title>
  <acronym>FLORET</acronym>
  <official_title>Open Label, Multi-centre, Parallel Group Study to Compare the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Febuxostat Between Pediatric Patients (≥6&lt;18 Years of Age) and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the exposure of febuxostat in pediatric patients&#xD;
      (≥6&lt;18 years of age) and in adults suffering from hematological malignancies at intermediate&#xD;
      to high risk of TLS and to compare the effect in terms of serum uric acid levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the FLORET study it is planned to enroll 3 groups of patients in order to receive oral&#xD;
      administration (film-coated tablets) of two different dose levels of febuxostat: children&#xD;
      (from 6 to less than 12 years of age) will receive two different dose levels respectively;&#xD;
      adolescents (from 12 to less than 18 years of age) will receive 80 and 120 mg/day&#xD;
      respectively and adults (equal or major than 18 years of age) will receive 120 mg/day. The&#xD;
      two dose levels for children and adolescents groups were to be sequentially administered,&#xD;
      whereas the groups that will receive the first dose levels will simultaneously start the&#xD;
      treatment at the study beginning. The individual treatment duration will be of 7 to 9 days,&#xD;
      according to chemotherapy duration, as per Investigator's judgement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped as per EMA waiver granted on 20July2018.&#xD;
  </why_stopped>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)</measure>
    <time_frame>7 days</time_frame>
    <description>Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>7 days</time_frame>
    <description>Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Absorption Rate Constant (Ka)</measure>
    <time_frame>7 days</time_frame>
    <description>Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Area Under Curve (AUC)</measure>
    <time_frame>7 days</time_frame>
    <description>AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>7 days</time_frame>
    <description>Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Tmax</measure>
    <time_frame>7 days</time_frame>
    <description>Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)</measure>
    <time_frame>8 days</time_frame>
    <description>Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Laboratory Tumor Lysis Syndrome (LTLS)</measure>
    <time_frame>7 days</time_frame>
    <description>Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Tumor Lysis Syndrome (CTLS)</measure>
    <time_frame>7 days</time_frame>
    <description>Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Treatment Emergent Signs and Symptoms (TESS)</measure>
    <time_frame>Estimated maximum time frame: 27 days</time_frame>
    <description>Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)</measure>
    <time_frame>Estimated maximum time frame: 27 days</time_frame>
    <description>Number of participants affected by TESS from Screening Visit to End of Study Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status (PS) Evaluation</measure>
    <time_frame>Estimated maximum time frame: 27 days</time_frame>
    <description>Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Tumor Lysis Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Intervention is orally administered to patients in this arm.</description>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        male and female children of 6 to less than 12 years of age, adolescents of 12 to less than&#xD;
        18 years of age and adults from 18 years:&#xD;
&#xD;
          -  scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies&#xD;
&#xD;
          -  and at intermediate or high risk of TLS&#xD;
&#xD;
          -  and with no access to rasburicase&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with contraindications as per febuxostat summary of product characteristics&#xD;
&#xD;
          -  patients with severe renal insufficiency&#xD;
&#xD;
          -  patients with severe hepatic insufficiency&#xD;
&#xD;
          -  patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Locatelli, Prof, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Ospedale Pediatrico Bambino Gesù, Piazza Sant'Onofrio, 4, 00165 Rome, IT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Tsaritsa Yoanna</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem (paediatric)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOC Oncologia Medica A - Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.C. Azienda Ospedaliero - Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto G Gaslini Ospedale Pediatrico IRCCS</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <results_first_submitted>January 27, 2021</results_first_submitted>
  <results_first_submitted_qc>May 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2021</results_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TLS</keyword>
  <keyword>FLO-02</keyword>
  <keyword>Hematological Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03605212/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was screened and enrolled on 27 Feb 2017. The last patient completed the study on 16 Jul 2018. The study was conducted at 17 sites in 4 European countries.</recruitment_details>
      <pre_assignment_details>A total of 31 patients was screened, of whom 30 were enrolled and 28 completed the study regularly.&#xD;
Two enrolled patients were withdrawn from study drug treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="P5">
          <title>Adults</title>
          <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>DAY 1 before first febuxostat dosing.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="B5">
          <title>Adults</title>
          <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.33" spread="1.528"/>
                    <measurement group_id="B3" value="14.00" spread="1.000"/>
                    <measurement group_id="B5" value="60.21" spread="15.376"/>
                    <measurement group_id="B6" value="50.30" spread="24.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.13" spread="2.043"/>
                    <measurement group_id="B3" value="60.47" spread="19.747"/>
                    <measurement group_id="B5" value="75.60" spread="15.469"/>
                    <measurement group_id="B6" value="68.92" spread="21.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)</title>
        <description>Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)</title>
          <description>Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Apparent Volume of Distribution (Vd/F)</title>
        <description>Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Apparent Volume of Distribution (Vd/F)</title>
          <description>Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Absorption Rate Constant (Ka)</title>
        <description>Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Absorption Rate Constant (Ka)</title>
          <description>Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Area Under Curve (AUC)</title>
        <description>AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Area Under Curve (AUC)</title>
          <description>AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Maximum Plasma Concentration (Cmax)</title>
        <description>Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Maximum Plasma Concentration (Cmax)</title>
          <description>Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Tmax</title>
        <description>Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Tmax</title>
          <description>Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)</title>
        <description>Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)</description>
        <time_frame>8 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)</title>
          <description>Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Laboratory Tumor Lysis Syndrome (LTLS)</title>
        <description>Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Laboratory Tumor Lysis Syndrome (LTLS)</title>
          <description>Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Tumor Lysis Syndrome (CTLS)</title>
        <description>Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.</description>
        <time_frame>7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Tumor Lysis Syndrome (CTLS)</title>
          <description>Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Treatment Emergent Signs and Symptoms (TESS)</title>
        <description>Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.</description>
        <time_frame>Estimated maximum time frame: 27 days</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Treatment Emergent Signs and Symptoms (TESS)</title>
          <description>Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.</description>
          <population>Safety population</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESS grade &gt;/=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TESS grade &gt;/=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TESS/Drug Withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)</title>
        <description>Number of participants affected by TESS from Screening Visit to End of Study Visit.</description>
        <time_frame>Estimated maximum time frame: 27 days</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)</title>
          <description>Number of participants affected by TESS from Screening Visit to End of Study Visit.</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Status (PS) Evaluation</title>
        <description>Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).</description>
        <time_frame>Estimated maximum time frame: 27 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
          <group group_id="O5">
            <title>Adults</title>
            <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Status (PS) Evaluation</title>
          <description>Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the entire duration of a patient's study participation, i.e. approximately 3 weeks. In addition, if after the end of the study the Investigator became aware of any AEs or follow-up in AEs already recorded, this information could be recorded in the eCRF until it was available.</time_frame>
      <desc>Adverse Events were collected during Screening, i.e. after ICF signature until DAY 1, Visit 1 before first IMP intake and specifically Treatment Emergent Signs and Symptoms (TESSs) occurring from first IMP intake at Visit 1, DAY 1 until Visit 10, DAY 14.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4</title>
          <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
        <group group_id="E5">
          <title>Adults</title>
          <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)&#xD;
Febuxostat: Intervention is orally administered to patients in this arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septioc shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Enterobacter test positiv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>BP increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>White blood cell (WBC) count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypo HDL cholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Language disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting the results of this study for publication or presentation, the Investigator will allow the sponsor at least 60 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until the sponsor has reviewed/commented and agreed to any publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data for all outcome measures were not collected due to the paucity of data in the minor patient population and in agreement with EMA with the exceptions of the secondary outcome Assessment of Treatment Emergent Signs and Symptoms (TESS).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Angela Capriati, MD PhD - Corporate Director Clinical Sciences</name_or_title>
      <organization>Menarini Group</organization>
      <phone>+39 055 5680 ext 9990</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

